A novel mechanism of imeglimin‐mediated insulin secretion via the cADPR‐TRP channel pathway

AIMS/INTRODUCTION: Imeglimin is a novel oral hypoglycemic agent that improves blood glucose levels through multiple mechanisms of action including the enhancement of glucose‐stimulated insulin secretion (GSIS), however, the details of this mechanism have not been clarified. In the process of GSIS, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Funazaki, Shunsuke, Yoshida, Masashi, Yamada, Hodaka, Kakei, Masafumi, Kawakami, Masanobu, Nagashima, Shuichi, Hara, Kazuo, Dezaki, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756313/
https://www.ncbi.nlm.nih.gov/pubmed/34523242
http://dx.doi.org/10.1111/jdi.13669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756313/
https://www.ncbi.nlm.nih.gov/pubmed/34523242
http://dx.doi.org/10.1111/jdi.13669

Ejemplares similares